Managed to get my allocation on application. Very happy with the outcome.
Looking forward to seeing how the Noxopharm plan progresses. Key points for me are:
> NOX66 is a novel formulation of an effective compound - idronoxil
> Broad application across a range of cancers
> Trials in Eastern Europe is lower cost, the process quicker and apparently the ‘quality’ of patients is better since this may be their first treatment instead of last
> GK experienced at Human Trials and bringing drugs to market
All thumbs up for me plus a low enterprise value mean a strong investment opportunity I think. Let’s see if we start getting some good news in 2016 to set us up for a strong 2017
GLTA
- Forums
- ASX - By Stock
- NOX
- Listing today
Listing today
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.79M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4382 | 7.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 47390 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4382 | 0.072 |
1 | 14084 | 0.071 |
1 | 20260 | 0.070 |
1 | 10000 | 0.069 |
1 | 74000 | 0.067 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 47390 | 2 |
0.083 | 40000 | 1 |
0.084 | 13517 | 1 |
0.090 | 25689 | 3 |
0.091 | 10989 | 1 |
Last trade - 12.57pm 12/06/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
SPONSORED BY The Market Online